Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 3058 citing articles:

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension
Giuseppe Mancia, Reinhold Kreutz, Mattias Brunström, et al.
Journal of Hypertension (2023) Vol. 41, Iss. 12, pp. 1874-2071
Open Access | Times Cited: 1554
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
José A. Joglar, Mina K. Chung, Anastasia L. Armbruster, et al.
Circulation (2023) Vol. 149, Iss. 1
Open Access | Times Cited: 930
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Seth S. Martin, Aaron W. Aday, Zaid Almarzooq, et al.
Circulation (2024) Vol. 149, Iss. 8
Open Access | Times Cited: 914
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, et al.
Circulation (2022) Vol. 145, Iss. 18
Open Access | Times Cited: 638
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Salim S. Virani, L. Kristin Newby, Suzanne V. Arnold, et al.
Circulation (2023) Vol. 148, Iss. 9
Open Access | Times Cited: 565
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association
Chiadi E. Ndumele, Janani Rangaswami, Sheryl L. Chow, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1606-1635
Open Access | Times Cited: 384
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload
Wilfried Müllens, Jeroen Dauw, Pieter Martens, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 13, pp. 1185-1195
Open Access | Times Cited: 366
Heart Failure With Preserved Ejection Fraction
Margaret M. Redfield, Barry A. Borlaug
JAMA (2023) Vol. 329, Iss. 10, pp. 827-827
Closed Access | Times Cited: 295
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
Paul R. Kalra, John G.F. Cleland, Mark C. Petrie, et al.
The Lancet (2022) Vol. 400, Iss. 10369, pp. 2199-2209
Open Access | Times Cited: 251
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association
Chiadi E. Ndumele, Ian J. Neeland, Katherine R. Tuttle, et al.
Circulation (2023) Vol. 148, Iss. 20, pp. 1636-1664
Open Access | Times Cited: 236
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Pardeep S. Jhund, Toru Kondo, Jawad H. Butt, et al.
Nature Medicine (2022) Vol. 28, Iss. 9, pp. 1956-1964
Open Access | Times Cited: 201
Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association
Sadiya S. Khan, Josef Coresh, Michael Pencina, et al.
Circulation (2023) Vol. 148, Iss. 24, pp. 1982-2004
Closed Access | Times Cited: 189
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S179-S218
Open Access | Times Cited: 177
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Jiang-Hui Wang, Dominic J. Gessler, Wei Zhan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 176
Gliflozins in the Management of Cardiovascular Disease
Eugene Braunwald
New England Journal of Medicine (2022) Vol. 386, Iss. 21, pp. 2024-2034
Closed Access | Times Cited: 172
Diagnosis and Treatment of Acute Myocarditis
Enrico Ammirati, Javid J. Moslehi
JAMA (2023) Vol. 329, Iss. 13, pp. 1098-1098
Closed Access | Times Cited: 172
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines
Steve R. Ommen, Carolyn Y. Ho, Irfan M. Asif, et al.
Circulation (2024) Vol. 149, Iss. 23
Closed Access | Times Cited: 144
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Jan Biegus, Adriaan A. Voors, Sean P. Collins, et al.
European Heart Journal (2022) Vol. 44, Iss. 1, pp. 41-50
Open Access | Times Cited: 137
Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial
Jasper J. Brugts, Sumant P. Radhoe, Pascal R.D. Clephas, et al.
The Lancet (2023) Vol. 401, Iss. 10394, pp. 2113-2123
Open Access | Times Cited: 128
Blinded, randomized trial of sonographer versus AI cardiac function assessment
Bryan He, Alan C. Kwan, Jae Hyung Cho, et al.
Nature (2023) Vol. 616, Iss. 7957, pp. 520-524
Open Access | Times Cited: 125
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Heather L. Gornik, Herbert D. Aronow, Philip P. Goodney, et al.
Circulation (2024) Vol. 149, Iss. 24
Closed Access | Times Cited: 117
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
Jawad H. Butt, Mark C. Petrie, Pardeep S. Jhund, et al.
European Heart Journal (2023) Vol. 44, Iss. 13, pp. 1136-1153
Open Access | Times Cited: 116
Tricuspid Regurgitation
Rebecca T. Hahn
New England Journal of Medicine (2023) Vol. 388, Iss. 20, pp. 1876-1891
Closed Access | Times Cited: 110
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology
Marco Metra, Daniela Tomasoni, Marianna Adamo, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 6, pp. 776-791
Open Access | Times Cited: 101
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 94
Page 1 - Next Page

Scroll to top